Research Article

<figure><img src="image_1.png" /></figure>

TRANSPARENT PROCESS

<figure><img src="image_2.png" /></figure>

OPEN ACCESS

<figure><img src="image_3.png" /></figure>

Check for updates

# Vascular dysfunction is at the onset of oxaliplatin-induced peripheral neuropathy symptoms in mice

Sonia Taïb<fnref n="1" />,* Ⓒ, Juliette Durand<fnref n="1" />,*, Vianney Dehais<fnref n="1" />,†, Anne-Cécile Boulay<fnref n="1" />,†, Sabrina Martin<fnref n="1" />, Corinne Blugeon², Laurent Jourdren² Ⓒ, Rémi Freydier³, Martine Cohen-Salmon<fnref n="1" /> Ⓒ, Jamilé Hazan<fnref n="1" /> Ⓒ, Isabelle Brunet<fnref n="1" /> Ⓒ

Oxaliplatin-induced peripheral neuropathy (OIPN) is an adverse side effect of this chemotherapy used for gastrointestinal cancers. The continuous pain experienced by OIPN patients often results in the reduction or discontinuation of chemotherapy, thereby affecting patient survival. Several pathogenic mechanisms involving sensory neurons were shown to participate in the occurrence of OIPN symptoms. However, the dysfunction of the blood-nerve barrier as a source of nerve alteration had not been thoroughly explored. To characterise the vascular contribution to OIPN symptoms, we undertook two comparative transcriptomic analyses of mouse purified brain and sciatic nerve blood vessels (BVs) and nerve BVs after oxaliplatin or control administration. These analyses reveal distinct molecular landscapes between brain and nerve BVs and the up-regulation of transcripts involved in vascular contraction after oxaliplatin treatment. Anatomical examination of the nerve yet shows the preservation of BV architecture in the acute OIPN mouse model, although treated mice exhibit both neuropathic symptoms and enhanced vasoconstriction reflected by hypoxia. Moreover, vasodilators significantly reduce oxaliplatin-induced neuropathic symptoms and endoneurial hypoxia, establishing the key involvement of nerve blood flow in OIPN.

DOI 10.26508/lsa.202402791 | Received 23 April 2024 | Revised 12 November 2024 | Accepted 12 November 2024 | Published online 22 November 2024

## Introduction

Chemotherapy-induced peripheral neuropathy (CIPN) is a detrimental side effect of cancer treatment using neurotoxic chemotherapeutic agents including platinum compounds, taxanes, vinca alkaloids, and proteasome inhibitors (Dorsey et al, 2019). CIPN sensory symptoms include acute burning or stabbing pain, tingling and numbness of the hands and feet, and increased sensitivity to cold temperatures (Müller et al, 2021). These sensory symptoms

tend to be more prominent than motor or autonomic dysfunction, although their association is observed in CIPN patients (Staff et al, 2017). The patients' quality of life is significantly reduced because of continuous allodynia and paresthesia, which may result in the reduction or discontinuation of chemotherapy and thereby impact both treatment efficacy and patient survival (Cavaletti & Marmiroli, 2010; Burgess et al, 2021). Moreover, CIPN may be long-lasting or permanent even after the cessation of cancer treatment, whereas no efficient cure capable of preventing its occurrence or improving its long-term course has been developed to date (Cavaletti & Marmiroli, 2015).

Chemotherapeutic agents lead to neurotoxicity through a variety of molecular and cellular mechanisms that may predominantly affect diverse neuronal populations but ultimately trigger dying-back axonopathy and to a lesser extent neuronopathy (Park et al, 2023). The pathogenic mechanisms involved in CIPN depend on the drug mode of action and include distinct subcellular processes such as nuclear or mitochondrial DNA damage, disruption of microtubule dynamics, altered mitochondrial function, and perturbed ion channel activity (Park et al, 2023). Among chemotherapeutic agents simultaneously acting at different subcellular levels, platinum-based drugs are the most neurotoxic, with oxaliplatin causing the highest prevalence of CIPN (70–85% of patients; Argyriou et al, 2013; Burgess et al, 2021). Oxaliplatin is commonly used for the treatment of gastrointestinal solid tumours and particularly in first-line chemotherapy for advanced colorectal cancer (Grothey & Venook, 2018), the second most deadly cancer worldwide.

Although the molecular and cellular mechanisms leading to chemo-induced neuropathic pain are far from being deciphered, the neuronal component of CIPN has been extensively explored in an attempt to identify therapeutic solutions to alleviate symptoms in cancer patients, with very limited therapeutic success. However, the impairment of the blood-nerve barrier (BNB) has recently emerged as a key mechanism triggering neuropathic phenotype initiation in several preclinical neuropathic pain models of

<footnote n="1">¹Center for Interdisciplinary Research in Biology (CIRB), Collège de France, CNRS UMR 7241, INSERM U1050, Université PSL, Paris, France
²Genomic Facility, Institut de Biologie de l'ENS (IBENS), École Normale Supérieure, CNRS UMR 8197, INSERM U1024, Université PSL, Paris, France
³HydroSciences Montpellier, Université de Montpellier, CNRS, IRD, Montpellier, France</footnote>

<footnote>Correspondence: isabelle.brunet@college-de-france.fr</footnote>

<footnote>*Sonia Taib and Juliette Durand contributed equally to this work</footnote>

<footnote>†Vianney Dehais and Anne-Cécile Boulay contributed equally to this work</footnote>
traumatic nerve injury (Reinhold et al, 2023), suggesting a possible role for the nervous vasculature. Indeed, peripheral nerves are highly vascularized from embryonic day E16 (Taib et al, 2022) and critically rely on blood supply to ensure axon structure and function. Furthermore, in the development of neuropathic pain associated with diabetic peripheral neuropathy, alteration of blood flow patterns through the *vasa nervorum* has been implicated (Archer et al, 1984; Nukada, 2014). In addition, reduced blood flow perfusing peripheral nerves was also suggested to be associated with allodynia in mouse models of CIPN (Gauchan et al, 2009; Ogihara et al, 2019). Given that oxaliplatin is injected intravenously, a key vascular component giving rise to nerve dysfunction and neuropathic symptoms remains to be thoroughly characterised in oxaliplatin-induced peripheral neuropathy (OIPN).

This prompted us to first compare vascular sciatic nerve specificities and properties with respect to the brain vasculature. We also explored whether and how the blood vessels of sciatic nerve from animals injected with oxaliplatin were affected compared with those from sham control animals. To this end, we achieved a comprehensive study at molecular, anatomical, and functional levels. We here postulate that the vascular integrity within peripheral nerves could be fine-tuned by a balance of vascular permeability and contractility, maintaining peripheral nerve homeostasis and subjected to perturbations in OIPN condition.

## Results

### An optimised method to isolate intact blood vessels from mouse brain and sciatic nerve

Given that most anti-cancer drugs, including oxaliplatin, are unable to cross the blood-brain barrier (BBB) (Achar et al, 2021), when they specifically target peripheral neurons, we first aimed at comparing the vascular properties of the *vasa nervorum* and the BBB. To this end, we optimised and adapted to peripheral nerves a reported method designed to purify mouse brain vessels (Fig 1A). This protocol includes a partial basal lamina enzymatic digestion to remove non-vascular (glia and neuronal) associated elements (Boulay et al, 2017, 2019). The purified blood vessels (BV) from both adult mouse sciatic nerves (snBV) and brain (brBV) showed a physiological expression of the endothelial cell marker *Pecam-1/CD31* as shown in qRT-PCR (Fig 1B-D) where it appeared as expected enriched in the BV compared with the entire tissue (Fig 1B) and by snBV immunostaining (Fig 1E, left panel). The isolated snBV showed a continuous staining with isolectin B4 labeling the basal lamina surrounding the endothelial cell layer (Fig 1E, middle panel), which further suggested the BV integrity. This optimised protocol allowed the vascular smooth muscle cells (vSMC) to remain attached to the isolated snBV as established by both the expression of *Sm22a* transcript in qRT-PCR experiments (Fig 1C and D) and immunostaining of alpha-smooth muscle actin (SMA, Fig 1E, right panel). Finally, the absence of neuronal (Tuj1) and glial (Gfap, S100b, Mpz, and Prx) marker transcripts in snBV (Fig 1C) and brBV (Fig 1D) indicated that our purified BV preparations were devoid of any neuronal or glial contaminations.

### Molecular profiling of purified sciatic nerve and brain blood vessels

To determine the molecular identity of the *vasa nervorum* and compare it with one of the most selective barriers of the body, the BBB, we undertook a comparative transcriptomic analysis between isolated adult mouse snBV and brBV using bulk RNA sequencing. Notably, the overall analysis using an adjusted P-value < 0.001 and log₂ fold change < -1.5 or log₂ fold change > 1.5 resulted in the identification of 2,524 commonly expressed transcripts, whereas specific genes were considered when, in addition to those parameters, a given gene was not detected above 500 reads in brain (snBV specific) or in the nerve (brBV specific). It reveals 469 mRNAs highly enriched in snBV (snBV specific) and 502 mRNAs highly enriched in brBV (brBV specific) mRNAs (Fig 2A). Assessing the mean expression level of differentially expressed genes (DEGs) in snBV or brBV showed an enriched gene set in each compartment (Fig 2B). To better characterise the molecular properties of the *vasa nervorum*, which would necessarily underlie its contribution to nerve physiology and physiopathology, we selected two snBV-highly enriched DEGs, *Fabp4* and *Plvap*, and four genes commonly expressed in both datasets and known for their key function at the BBB, *Tjp1/ZO-1*, *Abcg2/BCRP* and *Abcb1a*, *Abcb1b/ABCB1* (Fig 2B). For the snBV-enriched DEGs, *Fabp4* and *Plvap* were chosen according to their distinct levels of expression (Fig 2B) and respective role in active (*Fabp4* encoding Fatty Acid Binding Protein 4 [FABP4]; Elmasri et al, 2009; Jabs et al, 2018) or passive (*Plvap* encoding Plasmalemma vesicle-associated protein -[PLVAP]; Chang et al, 2023) transport across the vessel wall. In addition, the structural and functional integrity of the BBB is directly controlled by *Tjp1-encoding* ZO-1-positive tight junctions between brain endothelial cells (Huber et al, 2001). Likewise, *Abcg2-encoding* BCRP and *Abcb1-encoding* ABCB1 are critical transporters at the BBB that restrict the brain permeability to its physiological substrates and anti-cancer drugs in vivo (Cisternino et al, 2004). Addressing the expression and indirectly the potential contribution of these selected genes to the blood-nerve barrier was thus of high interest.

The *vasa nervorum* is composed of different anatomical compartments with respect to the position of myelinated axon fascicles (see Fig 2C; Richner et al, 2018): (i) the vessels located within each axon fascicle belong to the endoneurium, (ii) those localized at the periphery of axon fascicles are from the perineurium, whereas (iii) those running along the external side of the nerve belong to the epineurium. The epineurial, perineurial, and endoneurial BVs run longitudinally along the nerve with perpendicular communicating branches, which altogether provides an adequate blood supply for peripheral nerve homeostasis and function. Aiming at exploring the expression pattern of our four candidates in the *vasa nervorum*, we carried out co-immunostaining experiments on sciatic nerve longitudinal sections or whole mount (Fig 2D and E). If *Tjp1/ZO-1* colocalised with endothelial cell marker *Pecam-1/CD31* at spots along both endoneurial and epineurial snBV (Fig 2D, upper panels), *Abcg2/BCRP* was only found colocalised with *Pecam-1/CD31* along endoneurial snBV (Fig 2D, middle panels). Reciprocally, the peripheral nerve-enriched PLVAP selectively colocalised with endothelial cells along epineurial snBV but was almost absent from endoneurial vessels (Fig 2D, lower panels). Moreover, the highly enriched FABP4 was indeed present all along the snBV without strong colocalisation
<figure><img src="image_4.png" /><figcaption>**Figure 1.** Purified blood vessels from mouse brain and sciatic nerve.</figcaption></figure>

(A) Schematic representation of the distinct samples: brBV (for brain blood vessels) and snBV (for sciatic nerve blood vessels). (B) qRT-PCR of *Pecam-1* from isolated blood vessels and from entire brains or sciatic nerves (SN). (C, D) qRT-PCR of transcripts encoding CD31/PECAM1, SM22a, TUBB3, GFAP, S100 β, MPZ, and PRX from sciatic nerve (C) or brain (D) isolated blood vessels. (E) Immunofluorescence staining of purified snBV: endothelial cells are labeled in magenta (CD31) and in green (IB4), whereas mural cells including vascular smooth muscle cells are stained in red. All cell nuclei are labeled in blue (Hoechst). Data information: n = 3 samples. Each sample represents two mice (four sciatic nerves or two brains). Scale bar is 50 µm.

to *Pecam-1/CD31* (Fig 2E, upper panels). Finally, a triple co-localization analysis enabled us to show that FABP4 was exclusively expressed along the veins of the sciatic nerve (sn), whereas arteries failed to show any staining (Fig 2E, lower panels). Furthermore, the strong staining of FABP4 along the veins failed to reveal any significant co-localization with either endothelial cells (*Pecam-1/CD31*) or vSMCs (α-SMA). Overall, these findings identify specific snBV markers that selectively label the distinct compartments or blood vessel types composing the *vasa nervorum*.

Different molecular pathways characterise the adult sciatic nerve or brain blood vessels

To further characterise the comprehensive molecular signature of
snBV and brBV, we performed gene ontology (GO) enrichment
analysis with the objective of identifying differentially enriched
pathways. Remarkably, three pathways related to “cilia,” “central
nervous system (CNS) functions,” and “channels/transporters”
turned out to be selectively significantly enriched in brBV (Fig 3A). If
<figure><img src="image_5.png" /><figcaption>**Figure 2. Protein expression pattern of the vasa nervorum.**</figcaption></figure>

(A) Number of commonly expressed, snBV (sciatic nerve blood vessels)- and brBV (brain blood vessels)-specific genes. Adjusted P-value cut-off <0.001; log₂ fold change < -1.5 or log₂ fold change > 1.5. Specific genes were considered when, in addition to those parameters, a given gene was not detected above 500 reads in the brain (snBV
the last two pathways were expected given the clear involvement of
the BBB in various CNS functions and its large repertoire of
transporters required for the fine-tuned crossing of molecules, a
brain-specific "cilia" pathway turned out to be relevant with regard
to recent studies revealing the presence of primary cilia in both
endothelial and smooth muscle cells of brBV (Zhang et al, 2019;
Thirugnanam et al, 2022). In terms of pathways significantly
enriched in snBV, several of them, including those associated
with "angiogenesis," "development/morphogenesis," "extracellular
matrix," "signalling pathways," or "transcription/translation regu-
lation" (Fig 3A) tend to characterise adult highly plastic vessels.
These data may indeed indicate that snBVs are more prone than
brBV to adapt, remodel and respond to homeostatic changes or
pathogenic insult in view of their large range of enriched "devel-
opmental" genes related to cell plasticity. Furthermore, the heat-
map (Fig 3B) showing the DEGs assembled by GO pathways further
confirmed significant differences between the snBV and brBV
vasculatures. In each pathway, some genes are commonly
expressed at similar levels by both vasculatures, as shown for
Cldn5/CLAUDIN-5, for example, in the "tight-junctions" dataset,
whereas others (e.g., Cldn1/CLAUDIN 1) display highly differential
expression patterns, being exclusively enriched in snBV or brBV (Fig
3B). Interestingly, some known oxaliplatin transporters (Fujita et al,
2019) appeared differentially expressed in the two vasculatures (Fig
3B): Octn2 (Slc22a5) and Oct3 (Slc22a3) were significantly more
expressed in snBV than in brBV that reciprocally showed enriched
Ctr1 (Slc7a1) or Mate1 (Slc47a1). These differences in oxaliplatin-
transporter expression could partly account for the different drug
permeability of the two barriers and the selective alteration of the
peripheral nervous system in OIPN.

The integrity of the vasa nervorum is preserved after oxaliplatin IV injections

To explore the impact of an intravenous (IV) oxaliplatin adminis-
tration on the vasa nervorum, we induced neuropathic symptoms in
mice by injecting three times oxaliplatin to reach a 30 mg/kg cu-
mulative dose and carried out behavioral tests to assess their
potential tactile allodynia and hypersensitivity to cold (Fig 4A).
Remarkably, oxaliplatin-treated mice showed a decrease in average
withdrawal threshold compared with control mice, which indicated
the development of tactile allodynia (Fig 4B). Furthermore, the
oxaliplatin-treated mouse group showed an increased number of
paw withdrawal in response to exposure to a cold plate (4°C)
compared with the control group, which revealed hypersensitivity
to cold (Fig 4C). We thus established that oxaliplatin-treated mice
developed significative neuropathic symptoms after three oxali-
platin IV injections with a cumulative dose of 30 mg/kg. We further
showed that these neuropathic symptoms were reversible as

oxaliplatin-treated mice lost their tactile allodynia (Fig S1A) and
cold hypersensitivity (Fig S1B) around 30 d after the first oxaliplatin
injection. We also established that the symptoms observed with
this cumulative dose of 30 mg/kg were conserved at 15 mg/kg (i.e., 3
injections of oxaliplatin at 5 mg/kg) but not at 6 mg/kg (3 injections
of oxaliplatin at 2 mg/kg; Fig S2).

Because oxaliplatin was intravenously injected for patient use,
we next investigated whether the overall morphology and com-
position of the mouse vasa nervorum was affected by an oxaliplatin
IV administration. Three-dimensional (3D) reconstructions of the
mouse sciatic nerve blood vessel network, based on CD31 immu-
nostaining (Fig 4D), failed to reveal any major changes of the vasa
nervorum between oxaliplatin-treated and control mice. Moreover,
the subsequent quantifications of blood vessel length (Fig 4E) and
branch point number (Fig 4F) per nerve did not show any significant
differences between oxaliplatin-treated and control mice. These
findings suggested that there was no vascular degeneration after
oxaliplatin injections in our mouse model. To further explore the
integrity of the vasa nervorum, we assessed the expression of both
the endothelial cell marker CD31 (Fig 4G) and a major blood-nerve-
barrier tight-junction protein (Ouyang et al, 2019), CLAUDIN-5 (Fig
4H). Both immunolabeling of CD31 and CLAUDIN-5 appeared con-
tinuous on the vasa nervorum of oxaliplatin-treated mice (Fig 4G
and H). In addition, qRT-PCR of Cldn5 mRNA relative expression
from mouse sciatic nerve failed to reveal any significant differences
between oxaliplatin-treated and non-treated mice (Fig 4I). Fur-
thermore, a 3D reconstruction of CLAUDIN-5-labeled vasa nervorum
(Fig S3A) did not show any statistical modifications in terms of
blood vessel length (Fig S3B) and branch point number (Fig S3C) as
shown on the CD31-stained BV network (Fig 4D).

As chronic administration of oxaliplatin not only causes OIPN in
rats but may also give rise to a loss of nerve fiber endings in their
epidermis (Boyette-Davis et al, 2011), we aimed to characterise the
density of intraepidermal nerve fiber (IENF) in our mouse model.
The immunostaining of mouse plantar hind paw skin with TUBB3
antibody, which turned here to allow visualization of more IENF
compared with PGP9.5 immunostaining (Fig S4A), showed that there
were no significant differences in IENF number, length, and volume
between oxaliplatin-treated and non-treated mice (Fig S4B-E).
Altogether, our data establish that both the vasa nervorum of the
sciatic nerve and the IENF density remain intact post oxaliplatin
injection during the acute OIPN phase, in which neuropathic
symptoms are still reversible.

The molecular landscape of the vasa nervorum is impacted by
oxaliplatin

Using the purification protocol described in Fig 1A, we isolated the
snBV from oxaliplatin-treated and sham-treated mice and carried

specific) or in the nerve (brBV specific). (B) Volcano plot of differentially expressed genes. Differentially expressed genes of interest are highlighted in white boxes. Adjusted *P*-value cut-off <0.001; log₂ fold change < -1 or log₂ fold change > 1. (C) Schematic representation showing the sciatic nerve structure. (D) Immunostaining on sciatic nerve longitudinal sections (14-µm thick). Blood vessels are stained in magenta (CD31/PECAM1). Two mutually expressed proteins, ZO-1 and BCRP and a nerve-enriched protein, PLVAP, are labeled in green. (E) Whole-mount immunostaining of a sciatic nerve. Endothelial cells are stained in magenta (CD31/PECAM1), smooth muscle cells in red (α-SMA), and the differentially expressed and nerve-specific protein FABP4 in green. A and V are respectively for artery and vein. Data information: Scale bar 30 µm.
A
Gene ontology enrichment analysis

<figure><img src="image_6.png" /></figure>

<figure><img src="image_7.png" /></figure>
out a comparative transcriptomic analysis through bulk RNA sequencing. In this comparison, samples were more homogenous as they were extracted from the nerve, and only differed from what IV was injected to the mice. In addition, as for the previous analysis, samples were made of heterogenous cell populations (EC and mural cells) which are known to underestimate differences between genes expression. Finally, we thought that for a better understanding of the etiology, as we were at the onset of OIPN symptoms, small molecular changes could still be meaningful. Thus, for this transcriptomic analysis, we modified our parameters. Our analysis resulted in the identification of 178 DEGs, including 53 down-regulated genes (adjusted P-value < 0.05, Log₂ Fold Change <0.5) and 125 up-regulated genes (adjusted P-value < 0.05, Log₂ Fold Change >0.5) in oxaliplatin-treated mice compared with control mice (Fig 5A). Notably, among the up-regulated DEGs, the corticosterone biosynthetic gene *Hsd11b1* (Fig 5A) was also found up-regulated in the bone marrow of rats treated with a combination of topotecan and oxaliplatin (Davis et al, 2015). Furthermore, the up-regulation of the microtubule-associated tumour suppressor gene *Mtus2*, shown to limit the metastatic activity of cancer cells (Kuo et al, 2017) and to express a long non-coding RNA *Mtus2-5* playing a key role in the angiogenesis of patients with a multifactorial thrombosis condition (Zhang et al, 2023), might be of interest as a downstream target of oxaliplatin IV treatment. Likewise, the up-regulated *Rasl10b* gene encoding a small GTPase with tumour suppressor potential (Zou et al, 2006), which was shown to regulate blood flow in the atrium (Rybkin et al, 2007), could also participate in the antitumoral response downstream of oxaliplatin. Thus, a number of identified DEGs seem promising for further investigation of oxaliplatin-induced molecular players and mechanisms underlying both the treatment efficiency and its detrimental consequences on the peripheral nervous system.

To characterise the biological pathways overrepresented after oxaliplatin administration, we performed a DEG enrichment analysis of GO and KEGG terms using the Metascape portal (Zhou et al, 2019). Interestingly, four of the pathways identified in the enrichment analysis were related to blood flow control, such as "circulatory system process," "oxytocin signalling pathway," "apelin signalling," and "vascular smooth muscle contraction" (Fig 5B). This analysis also pointed out that oxaliplatin seemed to specifically interfere with mural cell contractility, ion transport, intracellular adhesion, and extracellular matrix (Fig 5B). Altogether, this prompted us to hypothesize that oxaliplatin IV injections could alter the intra-nervous vasculature and thereby disrupt nerve homeostasis. To test this hypothesis, we further explored whether oxaliplatin treatment could selectively modify the expression pattern of its transporters, tight-junction proteins, and cues involved in vSMC contractile function as schematically summarized in Fig 5C. No significant differences in the expression levels of oxaliplatin transporter genes (Fig 5D) nor in the major tight-junction

proteins of peripheral nerve endothelial cells (Fig 5E) were detected between oxaliplatin-treated and control animals. Thus, the transport of oxaliplatin did not tend to be increased at the onset of the pathology, neither its influx from the blood to the endothelial cells nor its efflux towards the blood or the parenchyma. Furthermore, the permeability of the intraneural vessels did not appear to be altered either. Yet, several genes involved in the vSMC contraction pathway or more generally in vasoconstriction are significantly up-regulated in oxaliplatin-treated mouse *vasa nervorum* compared with that of control mice (Fig 5F), which was further confirmed for a subset of them by qRT-PCR on independent samples (Fig S5). Altogether, these results suggested that oxaliplatin interfered with snBV contractile function and could participate in OIPN development by restricting proper nerve perfusion.

## Vasodilators significantly alleviate oxaliplatin-induced neuropathic symptoms

To test the RNA-Seq prediction that oxaliplatin IV injection increased vasoconstriction of the *vasa nervorum*, which thereby led to the OIPN symptoms, we explored whether injecting two different vasodilators, tadalafil and ambrisentan, could counteract this deleterious effect of oxaliplatin treatment. Cues increasing vasodilation were previously reported to reduce some OIPN symptoms in mouse models (Gauchan et al, 2009; Ogihara et al, 2019). We thus chose to assess whether inhibiting the contraction using ambrisentan, inducing vasodilation with tadalafil or a potential synergistic effect of both drugs could alleviate the peripheral symptoms of our OIPN mouse model (Fig 6A). We intraperitoneally injected 10 mg/kg tadalafil every other day whereas 5 mg/kg ambrisentan was injected every day as shown on the timeline (Fig 6B). We next performed behavioral tests in between each oxaliplatin injection to monitor the development and progression of neuropathic symptoms (Fig 6B). Oxaliplatin-treated mice exhibited tactile allodynia after the first injection and until the end of the protocol (Fig 6C). The injection of ambrisentan significantly reduced oxaliplatin-induced tactile allodynia from the first oxaliplatin injection (Fig 6C). Likewise, tadalafil treatment, alone or in combination with ambrisentan significantly alleviated oxaliplatin-induced tactile allodynia, although from the second oxaliplatin injection onwards (Fig 6C). After the third IV injection of oxaliplatin and thus the end of the protocol, tadalafil seemed to more efficiently prevent oxaliplatin-induced allodynia than ambrisentan, alone or together with ambrisentan (Fig 6C). Furthermore, oxaliplatin-treated mice showed clear discomfort at lower temperatures compared with control mice (Fig 6D). When treated with ambrisentan or tadalafil, or with a combination of the two drugs, the oxaliplatin-induced cold hypersensitivity was significantly diminished after three oxaliplatin injections. Notably, the synergistic effect of the dual treatment with both ambrisentan and tadalafil seemed to more efficiently reduce the oxaliplatin-

**Figure 3.** Molecular signatures of sciatic nerve and brain blood vessels.

(A) Enriched pathways in snBV (sciatic nerve blood vessels) and brBV (brain blood vessels) gene sets. Mann-Whitney test, *P*-value <0.01. (B) Heatmap representation of differentially expressed genes of interest involved in different pathways: oxaliplatin transport, tight junctions, chemokines, transporters, extracellular matrix and angiogenesis. The five first differentially expressed genes on top are not associated with any specific pathways but were selected for their enrichment in snBV (*Fabp4*, *Plvap*) or commonly expressed in both tissues (*Abcg2*, *Abcb1a*, *Abcb1b*). Right: log₂ fold change between snBV and brBV. The color of the column refers to the adjusted *P*-value. Data information: n = 3 with 2 mice per sample.
<figure><img src="image_8.png" /><figcaption>Figure 4. Analysis of the *vasa nervorum* in mice developing neuropathic symptoms after oxaliplatin IV administration.</figcaption></figure>

(A) Schematic representation of oxaliplatin-induced peripheral neuropathy acute mice model representing oxaliplatin injection and behavioral test (Von Frey and cold plate) timepoints. (B) Paw withdrawal threshold before and after each injection of oxaliplatin (oxa) or glucose (sham) measured with Von Frey test. (C) Sensitivity to cold before and after each injection, with a temperature of 4°C during 2 min (D) 3D reconstruction of the blood vessel network based on CD31/Pecam-1 signal from cleared sciatic nerves. Branch points are represented in magenta. (E) Quantification of the blood vessel length per nerve volume. (F) Quantification of the number of blood vessel branch points per filament length. (G) 3D view (200-µm thick) of a sciatic nerve region from sham and oxa mice. CD31/PECAM1 is stained in green. (H) 3D view (200-µm thick) of a sciatic nerve region from sham and oxa mice (zoom on the right). CLDN5 is stained in magenta. (I) qRT-PCR of *Cldn5* mRNA. Data information; n = 5-6. Mann-Whitney test, two-tailed, \*P < 0.05, \*\*P < 0.01. (B, C) Supplemental test (not shown in graphs): Kruskal-Wallis test, (B): Sham ns, Oxa \*\*; (C): Sham ns, Oxa \*\*\*\*, with \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001. (D, G, H) Scale bar: (D): 100 µm, (G): 30 µm, (H): Left: 40 µm, zoom on the right panel: 20 µm.
<figure><img src="image_9.png" /></figure>

<figure><img src="image_10.png" /></figure>

<figure><img src="image_11.png" /></figure>

<figure><img src="image_12.png" /></figure>

<figure><img src="image_13.png" /></figure>

<figure><img src="image_14.png" /></figure>

<figure><img src="image_15.png" /></figure>

<figure><img src="image_16.png" /></figure>

<figure><img src="image_17.png" /></figure>

<figure><img src="image_18.png" /></figure>

<figure><img src="image_19.png" /></figure>

<figure><img src="image_20.png" /><figcaption>**Figure 5.** Transcriptomic analysis of the *vasa nervorum* molecular composition in an acute mouse model of oxaliplatin-induced peripheral neuropathy.</figcaption></figure>

(A) Volcano plot representation of differentially expressed genes, adjusted P-value cut-off <0.05; log₂ fold change < -0.5 or log₂ fold change > 0.5. (B) Metascape analysis. Top 15 pathways enriched in differentially expressed genes. Low logP values correspond to the most enriched pathways. (C) Schematic representation showing genes of interest in blood vessel biological processes. (D, E, F) Number of reads for mRNA encoding oxaliplatin transporters/tight-junction proteins/genes of interest involved in vascular smooth muscle contraction from RNA sequencing data. Data information: n = 3 with 2 mice per sample, adjusted P-value from DESeq2 analysis \*P < 0.05, \*\*P < 0.01.
<figure><img src="image_21.png" /></figure>

<figure><img src="image_22.png" /></figure>

<figure><img src="image_23.png" /></figure>

<figure><img src="image_24.png" /></figure>

<figure><img src="image_25.png" /></figure>

<figure><img src="image_26.png" /></figure>

<figure><img src="image_27.png" /></figure>
induced cold hypersensitivity compared with the single use of
tadalafil or ambrisentan (Fig 6D). We next ensured that the ad-
ministration of one of these vasodilative molecules, tadalafil, did
not interfere with the availability of oxaliplatin in various tissues,
for example, by blocking the transporters involved in the oxaliplatin
influx or efflux. We did not observe any significant differences in
platinum concentrations within the sciatic nerves, the dorsal root
ganglias (DRGs) (Fig 6E) and the plasmas (Fig 6F) of oxaliplatin-
treated mice and doubly treated (oxaliplatin + tadalafil) mice,
suggesting that tadalafil administration did not interfere with
oxaliplatin biodistribution. These results thereby suggested that
both ambrisentan and tadalafil could significantly alleviate oxaliplatin-
induced neuropathic symptoms, although with different efficacy
depending on the symptoms analyzed. Because the bioavailability
of oxaliplatin was not altered by the administration of tadalafil, this
strongly suggests that vasodilators reduce oxaliplatin-induced
neuropathic symptoms by increasing nerve perfusion and not by
modifying oxaliplatin accumulation in tissues.

Ambrisentan and tadalafil reduce oxaliplatin-induced
nervous hypoxia

The observation that vasodilators significantly reduced oxaliplatin-
induced tactile allodynia and cold hypersensitivity in mice
suggested that oxaliplatin could perturb nerve homeostasis via
reduced perfusion. A direct consequence of a reduced blood
perfusion rate in the nerve could be that the nervous tissue be-
comes hypoxic. To test this hypothesis, we carried out sciatic nerve
immunostaining with the transcription factor HIF-1α (Fig 7A), a key
marker for hypoxia (Guillemin & Krasnow, 1997). Because the re-
duction in peripheral nerve area may reveal nerve damage (Koike
et al, 2010), we estimated the HIF-1α-fluorescent-intensity-to-
sciatic-nerve-area ratio in oxaliplatin-treated mice with or with-
out vasodilative treatment (Fig 7B). Remarkably, oxaliplatin-treated
mouse sciatic nerves showed a significant increase in HIF-1α levels
(Fig 7A and B). Moreover, the co-administration of oxaliplatin with
vasodilative molecules (tadalafil and/or ambrisentan) drastically
reduced oxaliplatin-induced hypoxia of the sciatic nerve (Fig 7A and
B). It should here be noted that because tadalafil and ambrisentan
individually rescued oxaliplatin-induced increase in HIF-1α fluo-
rescent intensity, no synergistic effect could be detected for the
dual injection of these vasodilators (Fig 7B). These results were next
confirmed using Western blot analysis (Fig 7C). Indeed, a lower dose
of oxaliplatin (3 injections of 5 mg/kg), which was sufficient to
induce neuropathic symptoms (Fig S2), caused nerve hypoxia re-
versed by tadalafil administration (Fig 7C). To further assess the
involvement of the HIF-1α pathway, we analyzed the expression of a
HIF-1α downstream effector (Liu et al, 1995; Forsythe et al, 1996),

VEGF-A. Using qRT-PCR and Western blot analyses, we observed a
significant increase in the transcription of *Vegfa* (Fig 7D) and an
increase in VEGF-A protein expression (Fig 7E) in oxaliplatin-treated
mouse sciatic nerves. Notably, an increase in the VEGFR-1 receptor
was also detected by co-immunohistochemistry in intra-nervous
blood vessels of oxaliplatin-treated sciatic nerves. The recruitment
of this receptor to the nerve blood vessels is importantly reversed
by tadalafil administration (Fig S6A and B).

Discussion

To explore the molecular specificity of the BNB compared with one
of the most selective barrier of the body, the BBB, we developed a
protocol to purify intact fragments of the *vasa nervorum* from adult
mouse sciatic nerves and conducted a comparative transcriptomic
analysis between brain and sciatic nerve vasculature. Notably,
among numerous DEGs shown to be specifically expressed, or
significantly enriched, either in brain BVs (brBVs) or in sciatic nerve
BVs (snBVs), our analysis revealed the selective expression of some
transporters responsible for the uptake of a chemotherapeutic
drug, oxaliplatin, in brBVs or snBVs. Indeed, as for other platinum
salts used as anti-cancer drugs known to cause a common and
dose-limiting peripheral neuropathy, several transporters localized
to the cell membrane of dorsal root ganglion were associated with
oxaliplatin uptake and efflux across the plasma membrane: the
organic cation transporters OCT2, OCT3, and OCTN1/2, as well as the
copper transporter CTR1 were described to be preferentially in-
volved in oxaliplatin uptake, whereas copper P-type ATPase ATP7B
as well as multidrug resistance-associated protein 2 (MRP2) and
multidrug and toxin extrusion protein 1 (MATE1) would mediate the
efflux of oxaliplatin (Fujita et al, 2019; Gu et al, 2019; Cheng et al,
2023). Given that oxaliplatin treatment exclusively affects the pe-
ipheral nervous system, we searched for any selective expression
of these transporters in snBVs, which could underlie the patho-
genesis of OIPN. Interestingly, whereas *Mate1* and *Ctr1* transcripts
are significantly enriched in brBVs, *Octn2* and *Oct3* mRNAs are
reciprocally up-regulated in snBVs. These different levels of oxa-
liplatin transporter mRNAs may participate in underpinning the
selective toxicity of oxaliplatin onto peripheral nerves, particularly
because the genetic or pharmacological targeting of OCT2 was
recently shown to improve acute and chronic forms of neurotoxicity
in a mouse model of OIPN (Huang et al, 2020). However, a thera-
peutic approach aiming at targeting OCT2 to simultaneously pre-
vent OIPN (Nepal et al, 2022) and increase oxaliplatin efficiency in
some cancer treatment (Liu et al, 2016) might be difficult to im-
plement without further studies in both animal models and cohorts

**Figure 6.** Preventive administration of ambrisentan and tadalafil improves oxaliplatin-induced neuropathic symptoms without affecting its accumulation.

(A) Schematic representation of ambrisentan and tadalafil molecular targets. (B) Schematic representation of the timepoints in oxaliplatin, ambrisentan, tadalafil injections and behavioral tests (Von Frey and cold plate). (C) Paw withdrawal threshold before and after injections of oxaliplatin (oxa), ambrisentan (ABS), or tadalafil (TADA) or both (Oxa ABS TADA). (D) Sensitivity to cold before and after injections of oxaliplatin, ambrisentan, and tadalafil. The temperature starts à 20°C and the plate loses 2°C per min. The threshold represents the temperature of the first response to cold. (E, F): Platinum concentrations in sciatic nerves, dorsal root ganglias (E) and plasma (F) from sham, oxaliplatin-treated or doubly oxaliplatin + tadalafil-treated animals. (C, D, E, F) Data information: (C, D) n = 12 (except n = 11 for Oxa ABS TADA at post inj 3), (E, F) n = 5 (except n = 3 for sham). Mann-Whitney test, two-tailed: \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001. Supplemental tests (not shown in graphs). (C): Kruskal-Wallis Sham ns, Oxa ****, Oxa ABS ns, Oxa TADA ns, Oxa ABS TADA. \*(D): Kruskal-Wallis Sham ns, Oxa ns, Oxa ABS ns, Oxa TADA ns, Oxa ABS TADA ns. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.
<figure><img src="image_28.png" /><figcaption>Figure 7. Administration of ambrisentan and tadalafil reduces oxaliplatin-induced nerve hypoxia and HIF-1α downstream effector VEGF-A.</figcaption></figure>

(A) Immunostaining of sciatic nerve longitudinal sections with anti-HIF-1α antibody. Nerves dissected from sham and oxaliplatin-treated animals (10 mg/kg) or treated with oxaliplatin (10 mg/kg) + tadalafil (Oxa TADA) or ambrisentan (Oxa ABS) or tadalafil + ambrisentan (Oxa ABS TADA) were analyzed. Representative images for each condition are visualized using an intensity-based color-coded representation using imageJ (fire LUT lookup table) to assess HIF-1α intensity. Colors represent signal intensity scale in the range of 0–256 (arbitrary unit) for each condition. (B) Quantification of HIF-1α-positive areas normalized to the nerve area. (C) Western blot analysis of HIF-1α expression in whole nerve homogenate from mice treated with oxaliplatin (5 mg/kg), oxaliplatin (5 mg/kg) + tadalafil (10 mg/kg) and glucose (sham). (D) qRT-PCR analysis of Vegfa expression from whole sciatic nerve of oxaliplatin-treated mice (10 mg/kg) compared with control mice (sham). (E) Western blot analysis of VEGF-A expression in whole nerve homogenate from mice treated with oxaliplatin (10 mg/kg) or glucose (sham). Data information: n = 4–8, Mann–Whitney test, two-tailed, *P < 0.05, **P < 0.01, ***P < 0.001. Scale bar 50 µm. (F) Mann–Whitney test, two-tailed, *P-adjusted < 0.05.
of patients (Winter et al, 2017; Zheng et al, 2017). These data prompted us to further characterise the anatomy and the molecular composition of the *vasa nervorum* in a mouse model of OIPN.

Immunostaining analyses of 3D-transparized sciatic nerves allowed us to show that the global architecture of snBVs was not affected by acute oxaliplatin administration, although the mice exhibited robust neuropathic symptoms. So far, most mouse models of acute OIPN have been developed by single or repeated intraperitoneal injection(s) of oxaliplatin (Gauchan et al, 2009; Descoeur et al, 2011; Ogihara et al, 2019; Gould et al, 2021; Wang et al, 2023). Aiming at mimicking the patients' oxaliplatin administration and assessing the direct effect of oxaliplatin onto EC and mural cells composing the *vasa nervorum*, we investigated the relevance of a vascular component as the source of OIPN symptom initiation via intravenous injections of oxaliplatin. Our oxaliplatin-injected mice displayed notable mechanical allodynia and cold hypersensitivity, which confirmed the behavioral analyses of previous mouse models injected intraperitoneally with oxaliplatin (Descoeur et al, 2011; Ogihara et al, 2019; Gould et al, 2021). Furthermore, the intraperitoneal administration of a vasodilator, tadalafil, or an inhibitor of vasoconstriction, ambisentan, was sufficient to significantly prevent acute OIPN symptom occurrence as revealed by both Von Frey and cold plate behavioral tests. These findings imply that oxaliplatin induces reversible enhanced vasoconstriction as BVs are not physically altered but only impaired in their vasoreactivity, which may be rescued by the use of distinct vasodilating drugs (Gauchan et al, 2009; Ogihara et al, 2019; present study).

This early vascular dysfunction is corroborated by our comparative transcriptomic analysis of oxaliplatin- or vehicle-treated sciatic nerve BVs, which revealed a significant up-regulation of the vascular contraction pathway. Indeed, several genes involved in the regulation of vasoconstriction, including *Myh11*, *Acta2*, *Myl9*, and *Mylk* encoding structural proteins of vSMC contractile unit (Karimi & Milewicz, 2016) or *Ryr2* and *Ryr3* encoding the ryanodine receptors that participate in regulating vSMC contractility (Kaßmann et al, 2019; Pritchard et al, 2019) are all up-regulated in oxaliplatin-injected sciatic nerve BVs compared with controls. Interestingly, additional genes found up-regulated in oxaliplatin-administered mouse nerve BVs, such as *Grip2* and *Cnn1*, were respectively identified as regulators of vSMC contractility in cerebral arteries (Fouillade et al, 2013) and the aorta (Castro et al, 2012). These data are not only consistent with the rescue of oxaliplatin-induced neuropathic pain using vasodilators in our mouse model of acute OIPN but also suggest that this enhanced vasoconstriction may lead to a decrease in nerve perfusion and possibly hypoxia that would evidently perturb peripheral nerve homeostasis.

To assess the level of nerve hypoxia after administration of oxaliplatin, we explored the expression of the transcription factor HIF-1α (Guillemin & Krasnow, 1997) on intact sciatic nerves from oxaliplatin-treated mice with or without vasodilator administration. This analysis showed a substantial increase in HIF-1α, reflecting the nerve hypoxic state, in oxaliplatin-administered mice, whereas the vasodilating drugs restored nerve normoxia. An increase in HIF-1α subsequently triggered the increase in VEGF-A expression in our oxaliplatin-treated mice. Notably, an

overexpression of HIF-1α was detected by Western blot analysis from oxaliplatin-injected mouse sciatic nerves (Yang et al, 2019) and dorsal root ganglia (Wang et al, 2023), whereas this microcirculation hypoxia was associated with the formation of neutrophil extracellular traps (Wang et al, 2023). Interestingly, the increased levels of VEGF-A have been associated with neuropathic pain, through the activation of the neuronal VEGFR-1 signalling (Micheli et al, 2021). The increase in VEGF-A levels in our OIPN model could as well sensitize these neuronal receptors to induce their downstream signalling. In addition, we observed the recruitment of the VEGFR-1 receptor to the blood vessels of oxaliplatin-treated animals. The activation of the VEGF-A/VEGFR-1 pathway may lead to increased permeability of intra-nervous blood vessels (Shibuya, 2011), which could be implicated in the transition from acute to chronic phases of the disease. Importantly, the hypoxic response triggers the up-regulation of several genes, including those encoding α- and β-globins (Grek et al, 2011), the 5-amino-levulinate synthase (ALAS2, Hofer et al, 2003), interleukin-1β (IL1β, Gui et al, 2016), and apelin (APLN, Zhang et al, 2016) in various model systems. Yet, in our acute OIPN mouse model, seven of these genes, *Hbb-bs*, *Hba-a2*, *Hbb-bt*, *Hba-a1*, *Alas2*, *Il1b*, and *Apln*, turned out to be strikingly down-regulated in oxaliplatin-treated mouse nerve compared with controls. This finding, which partly matches a recent study showing a significant down-regulation of *Hba-a1*, *Hba-a2*, and *Alas2* in the dorsal root ganglia of mice injected with a single dose of oxaliplatin (Gould et al, 2021), further implicates the down-regulation of these genes in neuropathic pain physiopathology and suggests that oxaliplatin may participate in blocking the hypoxic response in addition to its induction of nerve vasoconstriction. Remarkably, alpha-globins were shown to control hypoxia-induced vasodilation by generating nitric oxide (NO), at the origin of the most potent vasodilatory pathway, via nitrite reduction (Keller IV et al, 2022). One could thus speculate that the lack of alpha-globin nitrite-reductase activity in our OIPN mouse model prevents the physiological hypoxia/NO-induced vasodilation, which led to the occurrence of neuropathic symptoms that may be rescued by an additional intake of vasodilators.

In conclusion, our molecular and functional results in a mouse model mimicking the administration of oxaliplatin in patients reveal a new role for blood flow regulation, which are essential for preventing or alleviating the onset of acute symptoms of OIPN. Our comprehensive analysis of the *vasa nervorum* provides strong evidence for a role of vascular dysfunction, leading to nerve hypoxia, in the early pathogenesis of OIPN. Remarkably, microvascular dysfunction and endoneurial hypoxia were shown to contribute to the genesis of neuropathic pain associated with traumatic nerve injury (Lim et al, 2015) and diabetic peripheral neuropathy (Tuck et al, 1984; Østergaard et al, 2015). Recently, the stabilization or overactivation of the HIF-1α signalling pathway, reflecting peripheral nerve hypoxia, has been similarly linked to the pathogenesis of both bortezomib- or paclitaxel-induced peripheral neuropathy (Ludman & Melemedjian, 2019; Kober et al, 2020). Our work thus opens up new therapeutic avenues for the treatment of different forms of CIPN in emphasizing the vascular contribution to nerve homeostasis and in providing preclinical evidence for vasomotion treatment repurposing. Evaluating the efficacy of vasodilators in chronic models of OIPN might be
critical to assess the duration of their preventive effect and inves-
tigate their innocuity on the primary antitumoral role of oxaliplatin in
cancer mouse models.

**Materials and Methods**

Animals

We used male C57BL/6JRj (Janvier-Labs) mice, aged 3-6 mo. All experiments and techniques complied with the ethical rules of the French Agency for Animal Experimentation (project numbers #11822, #30827, and #38199).

Drug administration

Oxaliplatin (Accord, kindly provided by Dr Salvatore Cisternino) was diluted in 5% glucose solution for a final concentration of 2, 5, or 10 mg/kg. A total of 100 µl was intravenously injected three times (i.e., a respective cumulative dose of 6, 15, or 30 mg/kg) to the animals. Animals from the sham group received similar injections of 5% glucose. Tadalafil (SML1877; Sigma-Aldrich) was resuspended in DMSO at a concentration of 5 mg/ml and given every other day by IP injection of 10 mg/kg, starting 2 d before the first oxaliplatin injection. Ambrisentan (SML2104; Sigma-Aldrich) was equally resuspended in DMSO at a concentration of 2 mg/ml and given every day by IP injection of 5 mg/kg, starting 2 d before the first oxaliplatin injection.

The Von Frey test

Mice were individually placed in plastic boxes on a wire mesh floor and habituated for 30 min before testing. Von Frey filaments (BioSeb) of different binding forces (from 0.07, 0.16, 0.4, 0.6, 1, to 1.4 g) were applied five times to the mid-plantar skin of each hind paw. A reaction was counted as positive if the mouse immediately lifted the paw in reaction to the filament. For a given filament strength, if the number of positive reactions was equal or higher than 3/5, the mechanical threshold was considered to be reached. If a mouse did not respond to the 1.4 g filament, an arbitrary score of 1.6 was assigned.

Cold plate test

Mice were placed in a clear plastic box and first habituated to the cold plate apparatus (Bioseb) primarily set at RT (25°C), then at 4°C. For measurement, mice were submitted to the cold plate at 4°C during 2 min and the number of responses to cold hyperalgesia was counted (paw lift, licking, jump). At the request of the French Ethical Committee, we next modified the test according to the following protocol: mice were placed on the plate at an initial temperature of 20°C, and the plate was programmed to reduce by 2°C/min. The first discomfort reaction shown by the mouse was recorded as the cold tolerance threshold.

Clearing and immunostaining of entire sciatic nerves

After euthanasia, sciatic nerves were dissected and fixed in 4% PFA overnight at 4°C. We next used the iDisco+ staining and clearing method (Renier et al, 2014). After three PBS washes, samples were permeabilized with a solution of PBS/0.2% Triton/2.3% Glycine/2% DMSO for 2 d at 37°C followed by a blocking step with a solution of PBS/0.2% Triton/10% DMSO/6% donkey serum for 2 d at 37°C. Nerves were then incubated with primary antibodies diluted in PBS/0.2% Tween 20/1% heparin (10 mg/ml)/5% DMSO/3% donkey serum during 3 d at 37°C. After five washes with PTwH solution (PBS/0.2% Tween 20/1% heparin), samples were incubated with secondary antibodies in PTwH/3% donkey serum during 3 d at 37°C. After 5 washes with PTwH, nerves were included in 1% agarose blocks. Dehydration was performed with methanol/H₂O series (20%, 40%, 60%, 80%, and 100% for 1 h each) at RT and incubated in 66% dichloromethane (DCM, Sigma-Aldrich)/33% methanol during 3 h. This was followed by two incubations with 100% DCM for 15 min each. Samples were next cleared with dibenzyl ether (DBE, Sigma-Aldrich) overnight. The list of all the antibodies used in this study is summarized in Table 1.

Quantification of cleared sciatic nerves vascularization

Cleared sciatic nerves were imaged with an ultramicroscope (Lavision Biotech), and the Imaris software (Bitplane) was used to develop a 3D reconstruction of the CD31 and CLDN5 staining with the function “surface” followed by “filament tracer” to quantify the total length and the branch point number of the vessel network.

Whole-mount and cryosection immunofluorescent staining

After euthanasia, sciatic nerves were dissected and fixed in a 4% PFA solution during 30 min at RT. The whole mounts were incubated in TNBT solution composed of Tris-HCl pH7.4/5 M NaCl/0.5% blocking reagent (Perkin)/0.5% Triton X-100 overnight at 4°C. Primary antibodies were diluted in the same solution and left with the samples overnight at 4°C. After washes with TNT solution (Tris-HCl pH7.4/5 M NaCl/0.05% Triton X-100), nerves were incubated with secondary antibodies diluted in TNBT solution during 3 h at RT. After washes with TNT solution and a final wash in PBS, entire sciatic nerves were mounted with Fluoromont (Dako). For cryosections, immediately after being dissected, sciatic nerves were embedded in OCT media and snap-freezed in liquid nitrogen, except for HIF-1α staining in which sciatic nerves were fixed in PFA overnight at 4°C and cryopreserved in 15% and 30% sucrose baths. Cryostat sections (14 µm) were fixed using ice-cold 100% methanol for 8 min then incubated in a blocking solution composed of 0.25% Triton X-100/10% FBS/PBS over 30 min at RT. Primary antibodies were diluted in the same solution, in which sections were incubated overnight at 4°C. After PBS washes, secondary antibodies were diluted in a 0.1% Triton X-100/1% FBS/PBS solution where sections were incubated for 2 h at RT. For VEGFR-1 staining, sciatic nerves were dissected and fixed in a 4% PFA solution during 4 h then cryopreserved in a 30% sucrose bath at 4°C overnight. Cryostat sections (14 µm) were permeabilized in 0.3% Triton X-100/PBS during 30 min at RT. After washes in PBS, sections were incubated in a blocking solution (10%
<table><caption>Table 1. Antibodies.</caption><thead><tr><th>Designation</th><th>Supplier and reference</th><th>Dilution</th><th>Structure/function</th></tr></thead><tbody><tr><td rowspan="2">Anti-CD31/PECAM1</td><td rowspan="2">BD Biosciences/Pharmingen</td><td>1:200 (blood vessel staining)</td><td rowspan="2">Endothelial cells</td></tr><tr><td>1:400 (Whole mount, sciatic nerve cryosections)</td></tr><tr><td rowspan="2">Anti-α-SMA Cy3</td><td rowspan="2">Sigma-Aldrich</td><td>1:200 (blood vessel staining)</td><td rowspan="2">Smooth muscle cells</td></tr><tr><td>1:400 (entire sciatic nerve)</td></tr><tr><td>Anti-isolectine B4 (IB4) 488</td><td>I21411; Invitrogen</td><td>1:100</td><td>Vascular membrane</td></tr><tr><td>Anti-PLVAP</td><td>553849; BD Pharmingen</td><td>1:200</td><td>Vascular transport</td></tr><tr><td>Anti-FABP4</td><td>15872-1-AP; Proteintech</td><td>1:200</td><td>Vascular transport</td></tr><tr><td>Anti-ZO-1</td><td>20742-1-AP; Proteintech</td><td>1:200</td><td>Tight junction in EC</td></tr><tr><td>Anti-BCRP</td><td>ALX-801-036; Enzo Life Sciences</td><td>1:200</td><td>Vascular transport</td></tr><tr><td>Anti-CLAUDIN-5</td><td>34-1600; Thermo Fisher Scientific</td><td>1:500</td><td>Tight junction in EC</td></tr><tr><td rowspan="2">Anti-HIF-1α</td><td rowspan="2">NB100-449SS; Novus</td><td>1:200 (IF)</td><td rowspan="2">Hypoxia-inducible factor 1 alpha</td></tr><tr><td>1:500 (WB)</td></tr><tr><td>Anti-PGP9.5</td><td>15503; Abcam</td><td>1:400</td><td>Neuronal biomarker</td></tr><tr><td>Anti-TUBB3</td><td>201202; BioLegend</td><td>1:400</td><td>Neuron cytoskeletal</td></tr><tr><td>Anti-VEGFR-1</td><td>AF471; R&amp;D</td><td>1:400</td><td>Vascular endothelial growth factor receptor 1</td></tr><tr><td>Anti-VEGF-A</td><td>AB46154; Abcam</td><td>1:500</td><td>Vascular endothelial growth factor A</td></tr><tr><td>Anti-H3</td><td>14269; Ozyme</td><td>1:1,000</td><td>Histone H3</td></tr><tr><td>Alexa fluor goat anti-rat 555</td><td>A21434; Invitrogen</td><td>1:400</td><td></td></tr><tr><td>Alexa fluor donkey anti-rabbit 488</td><td>A21206; Invitrogen</td><td>1:400</td><td></td></tr><tr><td>Alexa fluor donkey anti-rabbit 647</td><td>A31573; Invitrogen</td><td>1:500</td><td></td></tr><tr><td>Alexa fluor donkey anti-rabbit 555</td><td>A31572; Invitrogen</td><td>1:400</td><td></td></tr><tr><td>Alexa fluor goat anti-mouse IgG2a 555</td><td>A21137; Invitrogen</td><td>1:400</td><td></td></tr><tr><td>Alexa fluor donkey anti-goat 555</td><td>A21432; Invitrogen</td><td>1:400</td><td></td></tr><tr><td>Anti-rabbit IgG HRP</td><td>HAF008; R&amp;D</td><td>1:5,000</td><td></td></tr><tr><td>Anti-mouse IgG HRP</td><td>G-21040; Invitrogen</td><td>1:5,000</td><td></td></tr></tbody></table>

donkey serum/PBS) during 1 h at RT. Primary antibodies were diluted in the same solution, in which sections were incubated overnight at 4°C. After PBS washes, secondary antibodies were diluted in a 1% BSA/0.1% Triton X-100/PBS solution where sections were incubated for 1 h at RT.

## Immunostaining of IENF

Mice were euthanized by cervical dislocation and the paw skins were dissected and fixed in 4% PFA overnight at 4°C. These skins were then rinsed twice in PBS before being submitted to successive incubations at 10%, 20%, and 30% sucrose/PBS at 4°C for cryopreservation. The paw skins were next included in OCT and frozen in liquid nitrogen before being sectioned using a cryostat (25 or

100 µm). The sections were thawed for 30 min at RT, blocked for 30 min in 10% BSA/PBS and incubated overnight à 4°C with the primary antibody solution diluted in 1% BSA solution/0.3% Triton X-100. The slices were next rinsed three times in PBS and incubated for 2 h at RT with secondary antibodies diluted in 1% BSA. After two PBS baths, the sections were incubated with Hoechst (1:1,500) for 5 min and mounted with Fluoromont (Dako) after three baths of PBS.

## IENF quantification

Plantar paw skins (three to five sections per animal, n = 5) were imaged with Zeiss confocal LSM980 (40X lens). Using Fiji, the epidermal area was defined with the “Freehand Line” tool as the
nucleus-dense area and we counted the number of terminal nerve fibers labeled with the βIII tubulin (TUBB3) antibody that crossed this area. The density of IENF was evaluated by making the ratio of the number of TUBB3-positive fibers over the area of the epidermis. The length and volume of the fibers were quantified using Imaris software (Bitplane) and a 3D reconstruction of the TUBB3 staining within the epidermis area was developed with the function "surface."

## Sciatic nerve dissociation

After dissection, sciatic nerves were cut into 5-10 small pieces using scissors and incubated in a digestion solution (DMEM/FBS 10% with 5 mg/ml Collagenase type II, C2-22; Sigma-Aldrich) heated to 37°C for 25 min in a thermocycler with gentle agitation. Before starting, small pieces were mechanically dissociated by flushing them up and down 10 times with a 21 g needle. Then, every 5 min, mechanical dissociation was performed by gentle flushing up and down 10 times using a 26 G needle. After digestion, cells were pelleted by centrifugation at 15,300g and at 4°C for 10 s and resuspended in TRIzol reagent (Invitrogen) for RNA extraction.

## Purification of brain (brBV) and sciatic nerve (snBV) blood vessels

A protocol used for the purification of brain blood vessels (Boulay et al., 2017) was here adapted to the *vasa nervorum*. Briefly, sciatic nerves (four sciatic nerves were pooled for one preparation to generate enough material for transcriptomic analysis), and brains were enzymatically digested with Liberase DL (Roche) at 143 µg.ml⁻¹ and DNAse I (Sigma-Aldrich) at 107 µg.ml⁻¹ at 37°C for 45 min. After a centrifugation for 10 min at 2,000g, the pellets were resuspended in a solution of 18% Dextran/HEPES/HBSS. The solution was centrifuged for 15 min at 3,200g, and the pellets were resuspended in a solution of 1% BSA/HBSS/HEPES. The solution was next filtered using a 20-µm filter, and the filter containing the blood vessel fragments was washed with a 1% BSA solution then centrifuged at 2,000g for 5 min. The pellets containing the blood vessels were stored at -80°C.

## Immunostaining of purified blood vessels

One drop of the solution containing the purified blood vessels (see above) was put on a glass slide with 1 µl of Cell-Tak (Thermo Fisher Scientific). The sample was fixed in 4% PFA for 15 min at RT. After three washes in PBS, the vessel samples were blocked in a solution of 10% SVF/0.25% Triton X-100/PBS for 30 min. Primary antibodies were diluted in the same solution in which the samples were incubated overnight at 4°C. After PBS washes, the vessels were incubated with the secondary antibodies diluted in 1% SVF/0.1% Triton X-100/PBS for 2 h at RT, followed by an incubation with Hoechst (1:1,500) for 5 min.

## cDNA libraries and RNA sequencing

cDNA library preparation and Illumina sequencing were performed at the École Normale Supérieure genomic core facility (ENS Paris).

PolyA + mRNAs were purified from 300 ng of total RNA using oligo(dT) primers. Libraries were prepared using the strand specific RNA-Seq library preparation TruSeq Stranded mRNA kit (Illumina). They were next multiplexed by six on two high-output flow cells. A 75-bp single read sequencing was performed on a NextSeq 500 (Illumina). A mean of 49 ± 9 million passing Illumina quality filter reads was obtained for each of the 12 samples.

## Bioinformatics

The analyses were performed using the Eoulsan pipeline (Jourdren et al., 2012), including read filtering, mapping, alignment filtering, read quantification, normalization, and differential analysis. Before mapping, poly N read tails were trimmed, reads ≤40 bases were removed, and reads with quality mean ≤ 30 were discarded. Reads were then aligned against the *Mus musculus* genome from Ensembl version 88 using STAR (version 2.7.2d; Dobin et al., 2013). Alignments from reads matching more than once on the reference genome were removed using Java version of Samtools (Li et al., 2009). To compute gene expression, *M. musculus* General Transfer Format (GTF) genome annotation version 88 from Ensembl database was used. All overlapping regions between alignments and referenced exons were counted and aggregated by genes using HTSeq-count 0.5.3 (Anders et al., 2015). The RNA-Seq gene expression data and raw fastq files are available on the GEO repository (www.ncbi.nlm.nih.gov/geo/) under accession numbers: GSE255096 and GSE255097. The sample counts were normalized using DESeq2 1.8.1 (Love et al., 2014). Statistical treatments and differential analyses were also performed using DESeq2 1.8.1.

## Enrichment analysis

Enrichment analysis was conducted with Gene Ontology for BBB and BNB comparison and using Metascape for the oxaliplatin-treated and control mouse BNB comparison.

## qRT-PCR

Total vessel RNAs were extracted using the "Nucleospin RNA XS" kit (Macherey-Nagel) according to the supplier's protocol. Total nerve RNAs were extracted using TRIzol Reagent protocol (Invitrogen). The final RNA concentration (ng.µl⁻¹) was measured using a nanodrop spectrophotometer (Thermo Fisher Scientific) with an absorbance at 260 nm. After cDNA synthesis using superscript III reverse transcriptase (Invitrogen), qRT-PCR was performed with Bio-Rad CFX and associated software for data analysis. *Gapdh*, *Hprt1*, and *Actb* were used as reference genes for relative expression. The list of primers used is summarized in Table 2.

## Western blot analysis

Mouse sciatic nerves were lysed in a protein extraction buffer (50 mM Tris, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 1% SDS, 1% protease inhibitor) and homogenized with sterile 5-mm Stainless steel beads, using a Tissuelyser II (QIAGEN) for 2 min at 30 beats per second over two cycles. The samples were sonicated and the
<table><caption>Table 2. Primers.</caption><thead><tr><td>Gene name</td><td>Reference or sequence</td><td>Structure/function</td></tr></thead><tbody><tr><td>Actb encoding β-Actin</td><td>QT00095242; QIAGEN</td><td>Cytoskeletal (housekeeping gene)</td></tr><tr><td>Gapdh</td><td>QT01658692; QIAGEN</td><td>Metabolic enzyme (housekeeping gene)</td></tr><tr><td>Hprt1</td><td>QT00166768; QIAGEN</td><td>Metabolic enzyme (housekeeping gene)</td></tr><tr><td rowspan="2">Pecam-1</td><td>F GCACCCATCACTTACCACCT</td><td rowspan="2">Endothelial cells (EC)</td></tr><tr><td>R GCTCGTCCCCTCTTTCACA</td></tr><tr><td rowspan="2">Cldn5</td><td>F TAAGGCACGGGTAGCACTCA</td><td rowspan="2">Tight junction between EC</td></tr><tr><td>R GGACAACGATGTTGGCGAAC</td></tr><tr><td rowspan="2">Zo-1</td><td>F GTTGGTACGGTGCCTGAAAGA</td><td rowspan="2">Tight junction between EC</td></tr><tr><td>R GCTGACAGGTAGGACAGACGAT</td></tr><tr><td rowspan="2">Sm22a</td><td>F CAACAAGGGTCCATCCTACGG</td><td rowspan="2">Adult smooth muscle</td></tr><tr><td>R ATCTGGGCGGCCTACATCA</td></tr><tr><td rowspan="2">Mpz</td><td>F AAGAACATGATGGGCCTGGA</td><td rowspan="2">Myelin sheath</td></tr><tr><td>R TGAGGAGCAAGAGGAAAGCA</td></tr><tr><td rowspan="2">Prx</td><td>F TGAAGCTACCCACCCTCAAG</td><td rowspan="2">Schwann cells</td></tr><tr><td>R CTGACATTTTGGGCAGCTGT</td></tr><tr><td rowspan="2">Tuj1</td><td>F AGCGCATCAGCGTATACTACAA</td><td rowspan="2">Neuron cytoskeletal</td></tr><tr><td>R TAAAGTTGTCGGGCCTGAATAG</td></tr><tr><td rowspan="2">Gfap</td><td>F CACCTACAGGAAATTGCTGGAGG</td><td rowspan="2">Non-myelinating Schwann cells</td></tr><tr><td>R CCACGATGTTCCTCTTGAGGTG</td></tr><tr><td rowspan="2">S100 β</td><td>F CTGGAGAAGGCCATGGTTGC</td><td rowspan="2">Schwann cells</td></tr><tr><td>R CTCCAGGAAGTGAGAGAGCT</td></tr><tr><td>Acta2</td><td>Bio-Rad qMmuCID0006375</td><td>Smooth muscle cells</td></tr><tr><td>Myh11</td><td>Bio-Rad qMmuCID0019272</td><td>Smooth muscle cells</td></tr><tr><td>Mylk</td><td>Bio-Rad qMmuCID0005600</td><td>Smooth muscle cells</td></tr><tr><td>Ryr3</td><td>Bio-Rad qMmuCED0050099</td><td>Skeletal muscle contraction</td></tr><tr><td>Vegfr1</td><td>QT00096292; QIAGEN</td><td>Vascular endothelial growth factor receptor 1</td></tr><tr><td>Vegfa</td><td>QT00160769; QIAGEN</td><td>Vascular endothelial growth factor A</td></tr></tbody></table>

supernatants obtained after centrifugation (20,800g for 20 min at 4°C) were used as samples. The extracted proteins were assayed with the Pierce BCA Protein Assay Kit (Life technologies) by spectrophotometry using BSA as a standard. Equal quantities of proteins (20 µg) were denatured by heating in Laemmli buffer, DTT, then separated in a Mini-PROTEAN TGX Stain Free Gels 4–15% (Bio-Rad). The proteins were then transferred to a 0.2 µm PVDF membrane (Bio-Rad). The non-specific binding sites of the membrane were blocked in Tris buffer containing 1% Tween (TBS-T) supplemented with 5% milk powder, for 1 h at RT. The membrane was next incubated in TBS-T supplemented with 5% milk powder, mixed with anti-VEGF-A, anti-HIF-1α, or anti-H3 overnight at 4°C. After washing, it was incubated with antibodies conjugated with HRP peroxidase (1/5,000) for 1 h at RT. The revelation was made by chemiluminescence with the Supersignal ECL Plus or Femto kit (Thermo Fisher Scientific). The signals obtained were acquired on Fusion FX system. The level of chemiluminescence for each antibody was normalized to histone-H3 signal. HIF-1α single band was observed around 55 kD in the sciatic nerve (Fig 7C) whereas with the same

protocol a band around 100 kD is observed in brain protein extract (data not shown).

## Platinum concentration detection via mass spectrometry

Mice were euthanized by intraperitoneal (i.p.) injection of 400 mg/kg ketamine (Imalgene) and 20 mg/kg Xylazine (Rompun). Blood was collected directly from the heart on EDTA tubes (Microvette, Sarstedt), followed by intracardiac perfusion with PBS1X +/- (Life Technologies) over 5 min until exsanguination. Plasma was centrifuged for 10 min at 6,800g and 4°C, then stored at -80°C. After perfusion, sciatic nerves and DRG were dissected and frozen directly in liquid nitrogen, then stored at -80°C. Nerves and DRGs were cold-ground with sterile 5-mm Stainless steel beads, using a Tissuelyser II (QIAGEN) for 2 min at 30 beats per second over two cycles. Homogenates were resuspended in 500 µl ultrapure water and freeze-dried by vacuum evaporation for 2 h at 42°C. Eppendorf microtubes containing dry samples (sciatic nerves and DRGs) were rinsed with 10% HNO₃ (vol/vol), and the solutions were transferred
in Teflon beakers and evaporated at 80°C. In each sample, 1 ml of pure HNO₃ (67% vol/vol) was added to the residue, and closed Teflon beakers were place overnight on a hot plate at 100°C. Finally, the solutions were evaporated at 80°C and the residue dissolved in 10 ml of 1% HNO₃ (vol/vol) after 20 min in ultrasonic bath and 1 h on a hot plate at 100°C. To prepare the plasma samples for Platinum analysis with ICP-MS, a simple 1,000-fold dilution was made with a mixture of 1.5% TMAH (tetramethyl ammonium hydroxide) to dissolve the protein-rich liquids and 1% HNO₃. To check potential contaminations (reagents, vials...) during sample preparation, procedural blanks were prepared following the same protocols than the samples. Platinum concentrations were determined with the Thermo Fisher Scientific iCAP TQ ICP-MS (using the Kinetic Energy Discrimination mode and He as collision gas) at the "Plaforme AETE-ISO, OSU OREME, Université de Montpellier-France." An internal solution was added on-line to the samples to correct signal drifts. A calibration curve including four points (0, 1, 5, and 10 ppb) was analyzed every 20-30 samples. To check the accuracy of the results, sciatic nerve, DRG and plasma samples from sham control animals were doped with oxaliplatin, homogenized, prepared following the same protocol than the samples from treated animals and analyzed. The deviation from the theoretical value was less than 10% and the analytical error (relative SD) less than 5%. Procedural blank contribution for plasma and solid samples is less than 4% and 0.2%, respectively.

## Statistical analysis

Data shown on graphs are expressed as means and SEM. Graphs and statistical analyses were performed using R Studio and Graphpad Prism software. The different statistical tests used were specified in the Figure legends. Volcano plots were generated using Enhanced Volcano (https://bioconductor.org/packages/devel/bioc/vignettes/EnhancedVolcano/inst/doc/EnhancedVolcano.html) and the heatmap was performed using Superheat (Barter & Yu 2018) with R Studio.

## Supplementary Information

Supplementary Information is available at https://doi.org/10.26508/lsa.202402791.

## Acknowledgements

We thank Drs Nathalie Kubis, Pierre Lozeron, and Marc Pocard for valuable comments throughout the course of this study and insightful discussion on its clinical relevance. We thank Salvatore Cisternino, Camille Cotteret, and Camille Gons who provided us with Oxaliplatin. We also deeply thank all current and previous members of the Brunet laboratory for helpful comments and discussion on the project. We thank the ORION technological Core (IMACHEM-IBISA) at the CIRB-Collège de France for their assistance in image acquisition and scripts. We thank the Genomique ENS core facility, supported by the France Génomique national infrastructure, funded as part of the "Investissements d'Avenir" program managed by the Agence Nationale de la Recherche (contract ANR-10-INBS-0009). We thank the AETE-ISO platform, OSU-OREME/Université de Montpellier for the mass spectrometry analysis of the platinum concentration in our samples. This work was

supported by research grants from INSERM CoPoC NEUROPLAT, Fondation Collège de France NEUROCURE, the French "League against Cancer," and annual laboratory funding of I Brunet. Over the course of this project, S Taib was the recipient of fellowships from the "Ministère de l'Enseignement Supérieur et de la Recherche" (MESR), "Labex MemoLife/PSL University," and the French "League against Cancer." J Durand received a salary from a French National Research Agency (ANR) funding attributed to I Brunet and a fellowship from the ARC Cancer Foundation. A-C Boulay was supported by postdoctoral fundings from Fondation pour la Recherche sur la Sclérose En Plaques (ARSEP) and M Cohen-Salmon by FRM. V Dehais is a recipient of a PhD fellowship from the MESR.

## Author Contributions

S Taib: conceptualization, data curation, formal analysis, validation, investigation, visualization, and methodology.

J Durand: conceptualization, data curation, software, formal analysis, validation, investigation, visualization, methodology, and writing—original draft.

V Dehais: formal analysis, validation, investigation, visualization, and methodology.

A-C Boulay: formal analysis, investigation, and methodology.

S Martin: resources, formal analysis, validation, investigation, visualization, and methodology.

C Blugeon: data curation and methodology.

L Jourdren: data curation, formal analysis, and methodology.

R Freydyer: data curation, formal analysis, investigation, and methodology.

M Cohen-Salmon: methodology.

J Hazan: conceptualization, formal analysis, and writing—original draft, review, and editing.

I Brunet: conceptualization, resources, supervision, funding acquisition, validation, visualization, methodology, project administration, and writing—original draft, review, and editing.

## Conflict of Interest Statement

The authors declare that they have no conflict of interest.

## References

Achar A, Myers R, Ghosh C (2021) Drug delivery challenges in brain disorders across the blood-brain barrier: Novel methods and future considerations for improved therapy. *Biomedicines* 9: 1834. doi:10.3390/biomedicines9121834

Anders S, Pyl PT, Huber W (2015) HTSeq-a Python framework to work with high-throughput sequencing data. *Bioinformatics* 31: 166–169. doi:10.1093/bioinformatics/btu638

Archer AG, Roberts VC, Watkins PJ (1984) Blood flow patterns in painful diabetic neuropathy. *Diabetologia* 27: 563–567. doi:10.1007/s00416-004-0036-8

Argyriou AA, Cavaletti G, Briani C, Velasco R, Bruna J, Campagnolo M, Alberti P, Bergamo F, Cortinovis D, Cazzaniga M, et al (2013) Clinical pattern and associations of oxaliplatin acute neurotoxicity: A prospective study in 170 patients with colorectal cancer. *Cancer* 119: 438–444. doi:10.1002/cncr.27732

Barter RL, Yu B (2018) Superheat: An R package for creating beautiful and extendable heatmaps for visualizing complex data. *J Comput Graph Stat* 27: 910–922. doi:10.1080/10618600.2018.1473780
Boulay AC, Saubameá B, Adam N, Chasseigneaux S, Mazaré N, Gilbert A, Bahin M, Bastianelli L, Blugeon C, Perrin S, et al (2017) Translation in astrocyte distal processes sets molecular heterogeneity at the gliovascular interface. *Cell Discov* 3: 17005. doi:10.1038/celldisc.2017.5

Boulay AC, Mazare N, Saubamey B, Cohen-Salmon M (2019) Preparing the astrocyte perivascular endfeet transcriptome to investigate astrocyte molecular regulations at the brain-vascular interface. *Methods Mol Biol* 1938: 105–116. doi:10.1007/978-1-4939-9068-9_8

Boyette-Davis J, Xin W, Zhang H, Dougherty PM (2011) Intraepidermal nerve fiber loss corresponds to the development of taxol-induced hyperalgesia and can be prevented by treatment with minocycline. *Pain* 152: 308–313. doi:10.1016/j.pain.2010.10.030

Burgess J, Ferdousi M, Gosal D, Boon C, Matsumoto K, Marshall A, Mak T, Marshall A, Frank B, Malik RA, et al (2021) Chemotherapy-induced peripheral neuropathy: Epidemiology, pathomechanisms and treatment. *Oncol Ther* 9: 385–450. doi:10.1007/s40487-021-00168-y

Castro MM, Cena J, Cho WJ, Walsh MP, Schulz R (2012) Matrix metalloproteinase-2 proteolysis of calponin-1 contributes to vascular hypocontractility in endotoxemic rats. *Arterioscler Thromb Vasc Biol* 32: 662–668. doi:10.1161/ATVBAHA.111.242685

Cavaletti G, Marmiroli P (2010) Chemotherapy-induced peripheral neurotoxicity. *Nat Rev Neurol* 6: 657–666. doi:10.1038/nrneurol.2010.160

Cavaletti G, Marmiroli P (2015) Chemotherapy-induced peripheral neurotoxicity. *Curr Opin Neurol* 28: 500–507. doi:10.1097/WCO.0000000000000234

Chang TH, Hsieh FL, Gu X, Smallwood PM, Kavran JM, Gabelli SB, Nathans J (2023) Structural insights into plasmalemma vesicle-associated protein (PLVAP): Implications for vascular endothelial diaphragms and fenestrae. *Proc Natl Acad Sci U S A* 120: e2221103120. doi:10.1073/pnas.2221103120

Cheng F, Zhang R, Sun C, Ran Q, Zhang C, Shen C, Yao Z, Wang M, Song L, Peng C (2023) Oxaliplatin-induced peripheral neurotoxicity in colorectal cancer patients: Mechanisms, pharmacokinetics and strategies. *Front Pharmacol* 14: 1231401. doi:10.3389/fphar.2023.1231401

Cisternino S, Mercier C, Bourasset F, Roux F, Scherrmann JM (2004) Expression, Up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. *Cancer Res* 64: 3296–3301. doi:10.1158/0008-5472.can-03-2033

Davis M, Li J, Knight E, Eldridge SR, Daniels KK, Bushel PR (2015) Toxicogenomics profiling of bone marrow from rats treated with topotecan in combination with oxaliplatin: A mechanistic strategy to inform combination toxicity. *Front Genet* 6: 14. doi:10.3389/fgene.2015.00014

Descoeur J, Pereira V, Pizzoccaro A, Francois A, Ling B, Maffre V, Couette B, Busserolles J, Courteix C, Noel J, et al (2011) Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors. *EMBO Mol Med* 3: 266–278. doi:10.1002/emmm.201100134

Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR (2013) STAR: Ultrafast universal RNA-seq aligner. *Bioinformatics* 29: 15–21. doi:10.1093/bioinformatics/bts635

Dorsey SG, Kleckner IR, Barton D, Mustian K, O'Mara A, St. Germain D, Cavaletti G, Danhauer SC, Hershman D, Hohmann AG, et al (2019) The National Cancer Institute clinical trials planning meeting for prevention and treatment of chemotherapy-induced peripheral neuropathy. *J Natl Cancer Inst* 111: 531–537. doi:10.1093/jnci/djz011

Elmasri H, Karaaslan C, Teper Y, Ghelfi E, Weng MQ, Ince TA, Kozakewich H, Bischoff J, Catalerte S (2009) Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells. *FASEB J* 23: 3865–3873. doi:10.1096/fj.09-134882

Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL (1996) Activation of vascular endothelial growth factor gene transcription by

hypoxia-inducible factor 1. *Mol Cell Biol* 16: 4604–4613. doi:10.1128/MCB.16.9.4604

Fouillade C, Baron-Menguy C, Domenga-Denier V, Thibault C, Takamiya K, Huganir R, Joutel A (2013) Transcriptome analysis for Notch3 target genes identifies Grip2 as a novel regulator of myogenic response in the cerebrovasculature. *Arterioscler Thromb Vasc Biol* 33: 76–86. doi:10.1161/ATVBAHA.112.251736

Fujita S, Hirota T, Sakiyama R, Baba M, Ieiri I (2019) Identification of drug transporters contributing to oxaliplatin-induced peripheral neuropathy. *J Neurochem* 148: 373–385. doi:10.1111/jnc.14607

Gauchan P, Andoh T, Kato A, Sasaki A, Kuraishi Y (2009) Effects of the prostaglandin E1analog limaprost on mechanical allodynia caused by chemotherapeutic agents in mice. *J Pharmacol Sci* 109: 469–471. doi:10.1254/jphs.08325sc

Gould SA, White M, Wilbrey AL, Pór E, Coleman MP, Adalbert R (2021) Protection against oxaliplatin-induced mechanical and thermal hypersensitivity in *Sarm1-/-* mice. *Exp Neurol* 338: 113607. doi:10.1016/j.expneurol.2021.113607

Grek CL, Newton DA, Spyropoulos DD, Baatz JE (2011) Hypoxia up-regulates expression of hemoglobin in alveolar epithelial cells. *Am J Respir Cell Mol Biol* 44: 439–447. doi:10.1165/rcbm.2009-0307OC

Grothey A, Venook AP (2018) Optimizing adjuvant therapy for localized colon cancer and treatment selection in advanced colorectal cancer. *J Natl Compr Cancer Netw* 16: 611–615. doi:10.6004/jnccn.2018.0038

Gu J, Wang L, Li T, Tang S, Wang Y, Zhang W, Jiang X (2019) Role and mechanism of organic cation transporter 3 in oxaliplatin treatment of colon cancer in vitro and in vivo. *Oncol Rep* 42: 1355–1364. doi:10.3892/or.2019.7267

Gui W-S, Wei X, Mai C-L, Murugan M, Wu L-J, Xin W-J, Zhou L-J, Liu X-G (2016) Interleukin-1β overproduction is a common cause for neuropathic pain, memory deficit, and depression following peripheral nerve injury in rodents. *Mol Pain* 12: 1–15. doi:10.1177/1744806916646784

Guillemin K, Krasnow MA (1997) The hypoxic response: Huffing and HIFing. *Cell* 89: 9–12. doi:10.1016/s0092-8674(00)80176-2

Hofer T, Wenger RH, Kramer MF, Ferreira GC, Gassmann M (2003) Hypoxic up-regulation of erythroid 5-aminolevulinate synthase. *Blood* 101: 348–350. doi:10.1182/blood-2002-03-0773

Huang KM, Leblanc AF, Uddin ME, Kim JY, Chen M, Eisenmann ED, Gibson AA, Li Y, Hong KW, DiGiacomo D, et al (2020) Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice. *J Clin Invest* 130: 4601–4606. doi:10.1172/JCI136796

Huber JD, Egleton RD, Davis TP (2001) Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. *Trends Neurosci* 24: 719–725. doi:10.1016/s0166-2236(00)02004-x

Jabs M, Rose AJ, Lehmann LH, Taylor J, Moll I, Sijmonsma TP, Herberich SE, Sauer SW, Poschet G, Federico G, et al (2018) Inhibition of endothelial Notch signaling impairs fatty acid transport and leads to metabolic and vascular remodeling of the adult heart. *Circulation* 137: 2592–2608. doi:10.1161/CIRCULATIONAHA.117.029733

Jourdren L, Bernard M, Dillies MA, Le Crom S (2012) Eoulsan: A cloud computing-based framework facilitating high throughput sequencing analyses. *Bioinformatics* 28: 1542–1543. doi:10.1093/bioinformatics/bts165

Karimi A, Milewicz DM (2016) Structure of the elastin-contractile units in the thoracic aorta and how genes that cause thoracic aortic aneurysms and dissections disrupt this structure. *Can J Cardiol* 32: 26–34. doi:10.1016/j.cjca.2015.11.004

Kaßmann M, Szijártó IA, García-Prieto CF, Fan G, Schleifenbaum J, Anistan YM, Tabeling C, Shi Y, le Noble F, Witzenrath M, et al (2019) Role of ryanodine type 2 receptors in elementary Ca(2+) signaling in arteries and vascular adaptive responses. *J Am Heart Assoc* 8: e010090. doi:10.1161/JAHA.118.010090

Keller TCS 4th, Lechauve C, Keller AS, Broseghini-Filho GB, Butcher JT, Askew Page HR, Islam A, Tan ZY, DeLalio LJ, Brooks S, et al (2022) Endothelial
alpha globin is a nitrite reductase. *Nat Commun* 13: 6405. doi:10.1038/s41467-022-34154-3

Kober KM, Lee M-C, Olshen A, Conley YP, Sirota M, Keiser M, Hammer MJ, Abrams G, Schumacher M, Levine JD, et al (2020) Differential methylation and expression of genes in the hypoxia-inducible factor 1 signaling pathway are associated with paclitaxel-induced peripheral neuropathy in breast cancer survivors and with preclinical models of chemotherapy-induced neuropathic pain. *Mol Pain* 16: 1744806920936502. doi:10.1177/1744806920936502

Koike H, Atsuta N, Adachi H, Iijima M, Katsuno M, Yasuda T, Fukada Y, Yasui K, Nakashima K, Horiuchi M, et al (2010) Clinicopathological features of acute autonomic and sensory neuropathy. *Brain* 133: 2881-2896. doi:10.1093/brain/awq214

Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, 1000 Genome Project Data Processing Subgroup (2009) The sequence alignment/map format and SAMtools. *Bioinformatics* 25: 2078-2079. doi:10.1093/bioinformatics/btp352

Lim TKY, Shi XQ, Johnson JM, Rone MB, Antel JP, David S, Zhang J (2015) Peripheral nerve injury induces persistent vascular dysfunction and endoneurial hypoxia, contributing to the genesis of neuropathic pain. *J Neurosci* 35: 3346-3359. doi:10.1523/JNEUROSCI.4040-14.2015

Liu Y, Cox SR, Morita T, Kourembanas S (1995) Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer. *Circ Res* 77: 638-643. doi:10.1161/01.res.77.3.638

Liu Y, Zheng X, Yu Q, Wang H, Tan F, Zhu Q, Yuan L, Jiang H, Yu L, Zeng S (2016) Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin. *Sci Transl Med* 8: 348ra97. doi:10.1126/scitranslmed.aaf3124

Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 15: 550. doi:10.1186/s13059-014-0550-8

Ludman T, Melemedjian OK (2019) Bortezomib and metformin opposingly regulate the expression of hypoxia-inducible factor alpha and the consequent development of chemotherapy-induced painful peripheral neuropathy. *Mol Pain* 15: 1744806919850043. doi:10.1177/1744806919850043

Micheli L, Parisio C, Lucarini E, Vona A, Toti A, Pacini A, Mello T, Boccella S, Ricciardi F, Maione S, et al (2021) VEGF-A/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: Therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody. *J Exp Clin Cancer Res* 40: 320. doi:10.1186/s13046-021-02127-x

Müller J, Weiler M, Schneeweiss A, Haag GM, Steindorf K, Wick W, Wiskemann J (2021) Preventive effect of sensorimotor exercise and resistance training on chemotherapy-induced peripheral neuropathy: A randomised-controlled trial. *Br J Cancer* 125: 955-965. doi:10.1038/s41416-021-01471-1

Nepal MR, Taheri H, Li Y, Talebi Z, Uddin ME, Jin Y, DiGiacomo DF, Gibson AA, Lustberg MB, Hu S, et al (2022) Targeting OCT2 with duloxetine to prevent oxaliplatin-induced peripheral neurotoxicity. *Cancer Res Commun* 2: 1334-1343. doi:10.1158/2767-9764.crc-22-0172

Nukada H (2014) Ischemia and diabetic neuropathy. *Handb Clin Neurol* 126: 469-487. doi:10.1016/B978-0-444-53480-4.00023-0

Ogihara T, Nakagawa T, Hayashi M, Koyanagi M, Yonezawa A, Omura T, Nakagawa S, Kitada N, Imai S, Matsubara K (2019) Improvement of peripheral vascular impairment by a phosphodiesterase type 5 inhibitor tadalafil prevents oxaliplatin-induced peripheral neuropathy in mice. *J Pharmacol Sci* 141: 131-138. doi:10.1016/j.jphs.2019.10.005

Østergaard L, Finnerup NB, Terkelsen AJ, Olesen RA, Drasbek KR, Knudsen L, Jespersen SN, Frystyk J, Charles M, Thomsen RW, et al (2015) The effects of capillary dysfunction on oxygen and glucose extraction in diabetic neuropathy. *Diabetologia* 58: 666-677. doi:10.1007/s00125-014-3461-z

Ouyang X, Dong C, Ubogu EE (2019) In situ molecular characterization of endoneurial microvessels that form the blood-nerve barrier in normal human adult peripheral nerves. *J Peripher Nerv Syst* 24: 195-206. doi:10.1111/jns.12326

Park SB, Cetinkaya-Fisgin A, Argyriou AA, Höke A, Cavaletti G, Alberti P (2023) Axonal degeneration in chemotherapy-induced peripheral neurotoxicity: Clinical and experimental evidence. *J Neurol Neurosurg Psychiatry* 94: 962-972. doi:10.1136/jnnp-2021-328323

Pritchard HAT, Griffin CS, Yamasaki E, Thakore P, Lane C, Greenstein AS, Earley S (2019) Nanoscale coupling of junctophilin-2 and ryanodine receptors regulates vascular smooth muscle cell contractility. *Proc Natl Acad Sci USA* 116: 21874-21881. doi:10.1073/pnas.1911304116

Reinhold AK, Hartmannsberger B, Burek M, Rittner HL (2023) Stabilizing the neural barrier – a novel approach in pain therapy. *Pharmacol Ther* 249: 108484. doi:10.1016/j.pharmthera.2023.108484

Renier N, Wu Z, Simon DJ, Yang J, Ariel P, Tessier-Lavigne M (2014) iDISCO: a simple, rapid method to immunolabel large tissue samples for volume imaging. *Cell* 159: 896-910. doi:10.1016/j.cell.2014.10.010

Richner M, Ferreira N, Dudele A, Jensen TS, Vaegter CB, Gonçalves NP (2018) Functional and structural changes of the blood-nerve-barrier in diabetic neuropathy. *Front Neurosci* 12: 1038. doi:10.3389/fnins.2018.01038

Rybkin II, Kim M-S, Bezprozvannaya S, Qi X, Richardson JA, Plato CF, Hill JA, Bassel-Duby R, Olson EN (2007) Regulation of atrial natriuretic peptide secretion by a novel Ras-like protein. *J Cell Biol* 179: 527-537. doi:10.1083/jcb.200707101

Shibuya M (2011) Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: A crucial target for anti- and pro-angiogenic therapies. *Genes Cancer* 2: 1097-1105. doi:10.1177/1947601911423031

Staff NP, Grisold A, Grisold W, Windebank AJ (2017) Chemotherapy-induced peripheral neuropathy: A current review. *Ann Neurol* 81: 772-781. doi:10.1002/ana.24951

Taïb S, Lamandé N, Martin S, Coulpier F, Topilko P, Brunet I (2022) Myelinating Schwann cells and Netrin-1 control intra-nervous vascularization of the developing mouse sciatic nerve. *Elife* 11: e64773. doi:10.7554/eLife.64773

Thirugnanam K, Prabhudesai S, Van Why E, Pan A, Gupta A, Foreman K, Zennadi R, Rarick KR, Nauli SM, Palecek SP, et al (2022) Ciliogenesis mechanisms mediated by PAK2-ARL13B signaling in brain endothelial cells is responsible for vascular stability. *Biochem Pharmacol* 202: 115143. doi:10.1016/j.bcp.2022.115143

Tuck RR, Schmelzer JD, Low PA (1984) Endoneurial blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy. *Brain* 107 (Pt 3): 935-950. doi:10.1093/brain/107.3.935

Wang C-Y, Lin T-T, Hu L, Xu C-J, Hu F, Wan L, Yang X, Wu X-F, Zhang X-T, Li Y, et al (2023) Neutrophil extracellular traps as a unique target in the treatment of chemotherapy-induced peripheral neuropathy. *eBioMedicine* 90: 104499. doi:10.1016/j.ebiom.2023.104499

Winter S, Fisel P, Büttner F, Nies AT, Stenzl A, Bedke J, Schwab M, Schaeffeler E (2017) Comment on "Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin". *Sci Transl Med* 9: eaal2439. doi:10.1126/scitranslmed.aal2439

Yang Y, Hu L, Wang C, Yang X, Song L, Jiang C, Li Y, Li T, Liu W-T, Feng J (2019) p38/TF/HIF-α signaling pathway participates in the progression of CIPN in mice. *BioMed Res Int* 2019: 5347804. doi:10.1155/2019/5347804

Zhang J, Liu Q, Fang Z, Hu X, Huang F, Tang L, Zhou S (2016) Hypoxia induces the proliferation of endothelial progenitor cells via upregulation of
Apelin/APLNR/MAPK signaling. Mol Med Rep 13: 1801-1806.
doi:10.3892/mmr.2015.4691

Zhang H, Chalothorn D, Faber JE (2019) Collateral vessels have unique endothelial and smooth muscle cell phenotypes. *Int J Mol Sci* 20: 3608.
doi:10.3390/ijms20153608

Zhang L, Feng B, Zhou Z, Huang H, Yu C, Wang X, Xu C, Gao Y, Chen S (2023) Extracellular vesicles-transmitted long non-coding RNA MTUS2-5 promotes proliferation and vascularization of human vascular endothelial cells in patients with Budd-Chiari syndrome. *J Cell Mol Med* 27: 3431-3442. doi:10.1111/jcmm.17911

Zheng X, Liu Y, Yu Q, Wang H, Tan F, Zhu Q, Yuan L, Jiang H, Zeng S, Yu L (2017) Response to Comment on "Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin". *Sci Transl Med* 9: eaam6298. doi:10.1126/scitranslmed.aam6298

Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, Benner
C, Chanda SK (2019) Metascape provides a biologist-oriented resource
for the analysis of systems-level datasets. *Nat Commun* 10: 1523.
doi:10.1038/s41467-019-09234-6

Zou H, Hu L, Li J, Zhan S, Cao K (2006) Cloning and characterization of a
novel small monomeric GTPase, RasL10B, with tumor suppressor
potential. *Biotechnol Lett* 28: 1901-1908. doi:10.1007/s10529-006-9176-6

<figure><img src="image_29.png" /></figure>

License: This article is available under a Creative
Commons License (Attribution 4.0 International, as
described at https://creativecommons.org/
licenses/by/4.0/).